HC Wainwright Issues Negative Estimate for FULC Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.27) for the quarter, down from their prior estimate of ($0.22). HC Wainwright currently has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.16) EPS, FY2026 earnings at ($1.36) EPS, FY2027 earnings at ($1.35) EPS and FY2028 earnings at ($1.15) EPS.

Separately, Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Trading Up 1.5 %

Shares of FULC opened at $3.37 on Friday. Fulcrum Therapeutics has a twelve month low of $2.86 and a twelve month high of $13.70. The company’s fifty day simple moving average is $4.12 and its 200-day simple moving average is $4.61. The company has a market cap of $181.77 million, a P/E ratio of -10.87 and a beta of 2.03.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03).

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FULC. Mackenzie Financial Corp raised its holdings in shares of Fulcrum Therapeutics by 412.5% in the fourth quarter. Mackenzie Financial Corp now owns 118,025 shares of the company’s stock valued at $555,000 after acquiring an additional 94,997 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Fulcrum Therapeutics by 110.3% in the 4th quarter. Woodline Partners LP now owns 1,410,520 shares of the company’s stock valued at $6,629,000 after purchasing an additional 739,713 shares in the last quarter. Suvretta Capital Management LLC lifted its position in shares of Fulcrum Therapeutics by 182.3% in the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company’s stock worth $15,691,000 after purchasing an additional 2,155,675 shares during the period. Shay Capital LLC boosted its stake in shares of Fulcrum Therapeutics by 4.2% during the fourth quarter. Shay Capital LLC now owns 301,464 shares of the company’s stock valued at $1,417,000 after purchasing an additional 12,227 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Fulcrum Therapeutics by 224.0% during the fourth quarter. Millennium Management LLC now owns 76,123 shares of the company’s stock valued at $358,000 after purchasing an additional 52,628 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.